Galmed Pharmaceuticals (GLMD) Other Operating Expenses (2013 - 2025)
Galmed Pharmaceuticals (GLMD) posted quarterly Other Operating Expenses of $7.7 million for Q4 2025, up 38.02% year-over-year from $5.6 million in Q4 2024, and up 38.02% quarter-over-quarter from $5.6 million in Q4 2024.
Galmed Pharmaceuticals (GLMD) Other Operating Expenses (2013 - 2025) Analysis & Trends
Galmed Pharmaceuticals' Other Operating Expenses history runs 10 years deep, the most recent figure standing at $7.7 million for Q4 2025.
- In Q4 2025, Other Operating Expenses rose 38.02% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $7.7 million (up 40.45% YoY), while the FY2025 annual figure was $7.7 million, up 38.02% from the prior year.
- Other Operating Expenses for Q4 2025 stood at $7.7 million, up from $5.6 million in the prior quarter.
- The five-year high for Other Operating Expenses was $7.7 million in Q4 2025, with the low at -$278000.0 in Q2 2023.
- The 5-year median for Other Operating Expenses is -$23000.0 (2021), against an average of $1.0 million.
- The sharpest annual moves came in 2022 and 2023: Other Operating Expenses surged 125.0% in 2022, then sank 7050.0% in 2023.
- Galmed Pharmaceuticals' Other Operating Expenses stood at -$131000.0 in 2021, then soared by 77.1% to -$30000.0 in 2022, then soared by 116.67% to $5000.0 in 2023, then soared by 112160.0% to $5.6 million in 2024, then jumped by 38.02% to $7.7 million in 2025.
- Business Quant data shows GLMD's Other Operating Expenses at $7.7 million in Q4 2025, $5.6 million in Q4 2024, and -$97000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.75 Mn |
| Dec 31, 2024 | 5.61 Mn |
| Sep 30, 2024 | -97,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | -278,000.00 |
| Mar 31, 2023 | -172,000.00 |
| Sep 30, 2022 | -30,000.00 |
| Jun 30, 2022 | 4,000.00 |
| Mar 31, 2022 | 51,000.00 |
| Sep 30, 2021 | -131,000.00 |
| Jun 30, 2021 | -16,000.00 |
| Mar 31, 2021 | -227,000.00 |
| Sep 30, 2018 | -1.50 Mn |
| Jun 30, 2018 | -270,000.00 |
| Mar 31, 2018 | -268,000.00 |
| Dec 31, 2017 | -274,000.00 |
| Sep 30, 2017 | -273,000.00 |
| Jun 30, 2017 | -270,000.00 |
| Mar 31, 2017 | -268,000.00 |
| Dec 31, 2016 | -274,000.00 |